Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib first-line treatment in Caucasian patients with EGFR mutation-positive advanced or metastatic NSCLC
2010-018614-70Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started May 2010; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-018614-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018614-70.